Meeder Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History

Meeder Asset Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-12	Closed	–	–	2611
2020 Q1	$0	Sell	12 -46	-79%	-$873	﹤0.01%	2602
2019 Q4	$1K	Sell	58 -1,293	-96%	-$26.8K	﹤0.01%	2191
2019 Q3	$26K	Buy	1,351 +153	+13%	+$3.5K	﹤0.01%	1229
2019 Q2	$35K	Buy	1,198 +138	+13%	+$5.32K	﹤0.01%	1057
2019 Q1	$50K	Buy	1,060 +607	+134%	+$26.7K	﹤0.01%	885
2018 Q4	$16K	Buy	+453	New	+$21.3K	﹤0.01%	1133
2018 Q1	–	Sell	-3	Closed	–	–	1796
2017 Q4	$0	Buy	+3	New	+$182	﹤0.01%	1842
2017 Q3	–	Sell	-962	Closed	-$51K	–	1802
2017 Q2	$51K	Sell	962 -9	-0.9%	-$419	﹤0.01%	677
2017 Q1	$44K	Buy	+971	New	+$43.3K	﹤0.01%	630

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Meeder Asset Management's AERI Position: Q2 2020 in Review

Meeder Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q2 2020, closing a stake of 12 shares.

Meeder Asset Management first reported a position in AERI in Q1 2017 and held it in 9 quarters. The position peaked at $51K in Q2 2017. 155 funds tracked by Wall St. Rank hold AERI as of Q2 2020.

Meeder Asset Management reported no remaining Aerie Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Meeder Asset Management sold 12 Aerie Pharmaceuticals shares in Q2 2020.
Meeder Asset Management first reported a position in Aerie Pharmaceuticals in Q1 2017 and held it in 9 quarters.
Meeder Asset Management's Aerie Pharmaceuticals position peaked at $51K in Q2 2017.
155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.